{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:02:34Z","timestamp":1785301354904,"version":"3.55.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although Sodium-glucose transporter 2 (SGLT2) inhibitors provide substantial cardiovascular and renal benefits in type 2 diabetes mellitus (T2DM), their effects on sarcopenia-related body composition outcomes remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eight databases were searched for randomized controlled trials (RCTs) enrolling adults with T2DM that compared SGLT2 inhibitors with placebo or other glucose-lowering therapies, with a minimum follow-up of 12 weeks. A frequentist random-effects network meta-analysis was conducted. Primary outcomes were skeletal muscle mass (SMM) and lean mass (LM). Secondary outcomes included fat mass (FM), body fat percentage (PBF), visceral and subcutaneous fat, anthropometric measures, and safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-three RCTs involving 5,399 participants were included. No SGLT2 inhibitor significantly reduced SMM compared with placebo (all 95% confidence intervals crossed zero). For LM, empagliflozin (mean difference [MD] \u22121.22 kg, 95% CI \u22121.71 to \u22120.72), ipragliflozin (MD \u22120.99 kg, 95% CI \u22121.45 to \u22120.54), and canagliflozin (MD \u22120.80 kg, 95% CI \u22121.39 to \u22120.21) were associated with modest reductions in LM compared with placebo, whereas dapagliflozin and tofogliflozin showed neutral effects. In contrast, SGLT2 inhibitors consistently reduced FM (e.g., dapagliflozin MD \u22121.75 kg, 95% CI \u22122.63 to \u22120.87), PBF, visceral and subcutaneous fat, body weight (BW), body mass index (BMI), and waist circumference (WC). Safety analyses were limited by sparse networks and should be interpreted cautiously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In adults with T2DM, SGLT2 inhibitors reduce adiposity without clear evidence of clinically meaningful reductions in SMM. However, because muscle strength and physical performance outcomes were rarely reported, the current evidence is insufficient to determine the impact of SGLT2 inhibitors on sarcopenia risk. Findings for LM should be interpreted cautiously, as LM does not directly reflect muscle mass.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration:<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420261379719.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1877008","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:36:18Z","timestamp":1785299778000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of SGLT2 inhibitors on body composition and potential sarcopenia-related outcomes in type 2 diabetes mellitus: a network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaona","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Yellow River Central Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Yellow River Central Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yellow River Central Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yellow River Central Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afae052","article-title":"The conceptual definition of sarcopenia: Delphi consensus from the Global Leadership Initiative in Sarcopenia (GLIS)","volume":"53","author":"Kirk","year":"2024","journal-title":"Age Ageing"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-025-01004-y","article-title":"A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 consensus update","volume":"5","author":"Chen","year":"2025","journal-title":"Nat Aging"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12902-025-01935-y","article-title":"Sarcopenia in type 2 diabetes mellitus among Asian populations: prevalence and risk factors based on AWGS-2019: a systematic review and meta-analysis","volume":"25","author":"Yogesh","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/nu15194149","article-title":"Sarcopenia as a little-recognized comorbidity of type II diabetes mellitus: a review of the diagnosis and treatment","volume":"15","author":"Salom Vendrell","year":"2023","journal-title":"Nutrients"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn115791-20240709-00357","article-title":"Research progress on the relationship between sarcopenia and cognitive impairment in elderly patients with type 2 diabetes mellitus","volume":"17","author":"Zhang","year":"2025","journal-title":"Chin J Diabetes Mellitus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.064071","article-title":"Sarcopenia and cardiovascular diseases","volume":"147","author":"Damluji","year":"2023","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/nu13103519","article-title":"Metabolic syndrome and sarcopenia","volume":"13","author":"Nishikawa","year":"2021","journal-title":"Nutrients"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1203666","article-title":"Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61071152","article-title":"Effects of empagliflozin on sarcopenia risk, body composition, and muscle strength in type 2 diabetes: a 24-week real-world observational study","volume":"61","author":"\u00c7etin","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B14","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions (Version 6.5)","author":"Higgins","year":"2024"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PloS Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1169894","article-title":"Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks","volume":"128","author":"Blonde","year":"2016","journal-title":"Postgrad Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 weeks results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial","volume":"16","author":"Fadini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1542741","article-title":"Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial","volume":"12","author":"Fukada","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010259","article-title":"Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-week randomized controlled trial","volume":"9","author":"Han","year":"2020","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: a prospective randomized study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109781","article-title":"Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: a randomized, clinical trial","volume":"186","author":"Horibe","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cardfail.2021.07.022","article-title":"Effect of empagliflozin versus placebo on body fluid balance in patients with acute myocardial infarction and type 2 diabetes mellitus: subgroup analysis of the EMBODY trial","volume":"28","author":"Hoshika","year":"2022","journal-title":"J Card Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13098-023-00990-6","article-title":"SGLT2 inhibitor versus carbohydrate-restricted isocaloric diet: reprogramming substrate oxidation in type 2 diabetes","volume":"15","author":"Igarashi","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12985","article-title":"Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial","volume":"10","author":"Inoue","year":"2019","journal-title":"J Diabetes Investig"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15056","article-title":"Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study","volume":"25","author":"Kang","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0341","article-title":"Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients-a randomized controlled trial","volume":"84","author":"Kayano","year":"2020","journal-title":"Circ J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14059","article-title":"Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: a randomized, 24-week, open-label, controlled trial (STOP-OB)","volume":"22","author":"Kitazawa","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13750","article-title":"Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: a prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study)","volume":"21","author":"Koshizaka","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00949-0","article-title":"Comparison of visceral fat reduction by ipragliflozin and metformin in elderly type 2 diabetes patients: sub-analysis of a randomized-controlled study","volume":"12","author":"Koshizaka","year":"2021","journal-title":"Diabetes Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13340","article-title":"Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: subanalysis of a prospective, randomized, controlled study (PRIME-V study)","volume":"12","author":"Koshizaka","year":"2021","journal-title":"J Diabetes Investig"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13270","article-title":"Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: a randomized controlled study","volume":"11","author":"Nakaguchi","year":"2020","journal-title":"J Diabetes Investig"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15164","article-title":"Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: the BEYOND study","volume":"25","author":"Park","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14721","article-title":"The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: the SEESAW randomized, double-blind, placebo-controlled trial","volume":"24","author":"Sargeant","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2884","article-title":"Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: exploring human metabolites associated with visceral fat reduction","volume":"43","author":"Tsukagoshi-Yamaguchi","year":"2023","journal-title":"Pharmacotherapy"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13421","article-title":"Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: a multicentre, randomized, prospective, open-label, active-controlled study","volume":"20","author":"Tsurutani","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41387-021-00160-5","article-title":"Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus","volume":"11","author":"Wolf","year":"2021","journal-title":"Nutr Diabetes"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15249","article-title":"Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565\u2009years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)","volume":"25","author":"Yabe","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13179","article-title":"Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: a randomized, controlled trial","volume":"11","author":"Yamakage","year":"2020","journal-title":"J Diabetes Investig"},{"key":"B47","doi-asserted-by":"publisher","first-page":"17065","DOI":"10.1038\/s41598-022-21486-9","article-title":"Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin","volume":"12","author":"Zeng","year":"2022","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.6040\/j.issn.1671-7554.0.2019.253","article-title":"Dapagliflozin improves lipid metabolism and visceral adipose tissues in overweight and obese patients with type 2 diabetes","volume":"57","author":"Jiang","year":"2019","journal-title":"J Shandong Univ Health Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.12114\/j.issn.1007-9572.2020.00.591","article-title":"Effects of dapagliflozin on the adiponectin level, body fat distribution and bone mineral content of overweight type 2 diabetes mellitus patients","volume":"24","author":"Liang","year":"2021","journal-title":"Chin J Gen Pract"},{"key":"B50","article-title":"A randomised controlled study of the efficacy and safety of loxenatide versus canagliflozin in patients with type 2 diabetes mellitus with sarcopenia","author":"Zhang","year":"2024"},{"key":"B51","article-title":"Effect of dapagliflozin combined with metformin on muscle content in overweight and obese patients with type 2","author":"Zhang","year":"2023"},{"key":"B52","doi-asserted-by":"publisher","first-page":"106420","DOI":"10.1016\/j.ejim.2025.07.016","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on skeletal muscle","volume":"141","author":"St\u00f6llberger","year":"2025","journal-title":"Eur J Intern Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1220516","article-title":"Relationship between sodium-glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Xia","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279889","article-title":"Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"17","author":"Pan","year":"2022","journal-title":"PloS One"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.12.010","article-title":"A meta-analysis of body composition changes associated with long-term use of sodium-glucose cotransporter 2 inhibitors","volume":"32","author":"Yamamoto","year":"2026","journal-title":"Endocr Pract"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2023.10.004","article-title":"Sodium-glucose co-transporter 2 inhibitors and sarcopenia: a controversy that must be solved","volume":"42","author":"Afsar","year":"2023","journal-title":"Clin Nutr"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177885","article-title":"The effects of GLP-1 receptor agonists on body composition in patients with type 2 diabetes, overweight or obesity: a meta-analysis of randomized controlled trials","volume":"1003","author":"Lu","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16012","article-title":"Characterizing bodycomposition modifying effects of a glucagon-like peptide 1 receptor-based agonist: a meta-analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101620","article-title":"Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism","volume":"66","author":"Op den Kamp","year":"2022","journal-title":"Mol Metab"},{"key":"B60","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-024-67755-7","article-title":"Dapagliflozin improves skeletal muscle insulin sensitivity through SIRT1 activation induced by nutrient deprivation state","volume":"14","author":"Gao","year":"2024","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13098-023-01130-w","article-title":"Exercise mitigates dapagliflozin-induced skeletal muscle atrophy in STZ-induced diabetic rats","volume":"15","author":"Yang","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14097","article-title":"Long-term safety and efficacy of SGLT2 inhibitor use in older east Asians with type 2 diabetes","volume":"15","author":"Takahashi","year":"2024","journal-title":"J Diabetes Investig"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155585","article-title":"Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes","volume":"144","author":"Hashimoto","year":"2023","journal-title":"Metabolism"},{"key":"B64","article-title":"The effect of SGLT-2 inhibitor, empagliflozin, over sitagliptin on nerve and muscle health in patients with type 2 diabetes","volume-title":"Slctr\/2025\/013","year":"2025"},{"key":"B65","article-title":"A study comparing the effects of additional diabetes medications on blood sugar control in patients already taking DPP-4 inhibitors","volume-title":"Kct0010819","year":"2025"},{"key":"B66","article-title":"Comparison of metformin plus dapagliflozin versus metformin plus semaglutide on body fat percentage and muscle strength in patients with diabetes","volume-title":"Ctri\/2025\/01\/079703","year":"2025"},{"key":"B67","article-title":"A study to evaluate the efficacy and safety of enavogliflozin in elderly patients aged \u226565 years with type 2 diabetes (ENAVO-SENIOR)","volume-title":"Kct0010678","year":"2025"},{"key":"B68","article-title":"Tofogliflozin versus glimepiride on skeletal muscle mass in non-obese patients with type 2 diabetes: a multicenter randomized controlled trial","volume-title":"Jrcts041240011","year":"2024"},{"key":"B69","article-title":"Effect of loxenatide versus canagliflozin in patients with type 2 diabetes mellitus and sarcopenia","volume-title":"Chictr2300074382","year":"2023"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1877008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:36:30Z","timestamp":1785299790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1877008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":69,"alternative-id":["10.3389\/fendo.2026.1877008"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1877008","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1877008"}}